Serum concentrations of estriol vary widely after application of vaginal oestriol cream.
oestriol concentrations
pharmacodynamics
pharmacokinetics
vaginal oestriol cream
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
28
04
2020
received:
02
12
2019
accepted:
07
09
2020
pubmed:
1
11
2020
medline:
21
9
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
The aim of this study was to establish the pharmacokinetic profile of serum oestriol (E Ten women participated. Vaginal cream was omitted for ≥36 h prior to the study days. Blood sampling was performed for E E Postmenopausal E
Substances chimiques
Estrogens
0
Vaginal Creams, Foams, and Jellies
0
Estrone
2DI9HA706A
Estradiol
4TI98Z838E
Estriol
FB33469R8E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2354-2360Informations de copyright
© 2020 British Pharmacological Society.
Références
Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Maturitas. 2014;79:349-354.
Barlow DH, Cardozo LD, Francis RM, et al. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol. 1997;104:87-91.
Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23:514-522.
Rueda C, Osorio AM, Avellaneda AC, Pinzon CE, Restrepo OI. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20:321-330.
Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;26:15-28.
Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest. 1989;27(4):204-207.
Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145:371-379.
van Haaften M, Donker G, Haspels A, Thijssen J. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem. 1989;33:647-653.
Haspels A, Luisi M, Kicovic P. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Mauritas. 1981;3:321-327.
Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand. 1983;62:393-396.
Rotti K, Stevens J, Watson D, Longcope C. Estriol concentrations in plasma of normal, non-pregnant women. Steroids. 1975;25:807-816.
Barlow DH, Samsioe G, van Geelen JM. A study of European womens' experience of the problems of urogenital ageing and its management. Maturitas. 1997;27:239-247.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
Clark JH. A critique of Women's Health Initiative studies (2002-2006). Nucl Recept Signal. 2006;4:e023.
Lobo RA. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metabol. 2013;98:1771-1780.
Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018;29:1771-1776.
Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015;15:413-420.
Sood R, Warndahl RA, Schroeder DR, et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. Maturitas. 2013;74(4):375-382.
te West NID, Day RO, Hiley B, White C, Wright M, Moore KH. Estriol serum levels in new and chronic users of vaginal estriol cream: a prospective observational study. Neurourol Urodyn. 2020;39(4):1137-1144. https://doi.org/10.1002/nau.24331
Cicinelli E, Di Naro E, De Ziegler D, et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am J Obstet Gynecol. 2003;189(1):55-58.
Purves RD. Bias and variance of extrapolated tails for area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm. 1992;20(5):501-510.
Diggle PJ, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data. Oxford: Oxford University Press; 2002.
Team RC. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1-48.
Amemiya T. Tobit models: a survey. J Econom. 1984;24:3-61.
Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219-227.
Delgado JL, Estevez J, Radicioni M, Loprete L, Moscoso Del Prado J, Nieto Magro C. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric. 2016;19(2):172-180.
Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9:179-187.
Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556-562.
Oliveira Filho RV, Antunes NJ, Ilha JO, et al. Pharmacokinetics and pharmacodynamics of three dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women. Br J Clin Pharmacol. 2019;85(3):551-562.